🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

SeQuent Scientific gets EU GMP approval for tablets dosage form in Turkey

SeQuent Scientific Limited said that its tablets dosage manufacturing line in Turkey has secured the European Union good manufacturing practices approval (EU GMP approval).

The Mumbai-based pure-play animal health company said that the approval was complemented further by the renewal of EU GMP license for eight other manufacturing lines for multiple dosage forms. The dosage types include beta-lactam, terminal sterilization, non-beta lactam, mastitis, aerosol, powder beta-lactam, pesticide, and solids in Turkey.

Apart from the EU GMP, SeQuent Scientific’s Turkish manufacturing lines also have GMP certificates from Turkish, Ethiopian, Saudi, and Sudanese authorities.

SeQuent Scientific gets EU GMP approval for its tablets dosage manufacturing line in Turkey
SeQuent Scientific gets EU GMP approval for its tablets dosage manufacturing line in Turkey. Photo courtesy of Anita starzycka from Pixabay.

With the approvals, SeQuent Scientific’s subsidiary – Alivira, an animal health company, now has various EU GMP approved facilities around the world to enable it to better cater to the its customers’ requirements in the regulated markets of Europe, and also access to alternative manufacturing sites so that supply of high quality products is ensured.

SeQuent Scientific claims to be the third-largest player in the ruminant market in Turkey with more than 120 product registrations and a consolidated market share of around 10%. The company operates in the country through its fully-owned subsidiaries Provet and Topkim.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

Total
0
Shares
Related Posts
Read More

Octant’s OCT-980 gains FDA orphan status, but can an oral molecule slow inherited vision loss?

Octant has received FDA orphan drug designation for OCT-980, an investigational oral therapy targeting protein misfolding associated with inherited retinal degeneration. The regulatory milestone follows the first patient dosing in September and supports development of a potentially disease-modifying treatment for rhodopsin-associated autosomal dominant retinitis pigmentosa.